Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials

British Journal of Cancer

Volumn 78, Issue 11, 1998, Pages 1479-1487

  Aabo, K ^b   Adams, M ^b   Adnitt, P ^b   Alberts, D S ^b   Athanazziou, A ^b   Barley, V ^b   Bell, D R ^b   Bianchi, U ^b   Bolis, G ^b   Brady, M F ^b   Brodovsky, H S ^b   Bruckner, H ^b   Buyse, M ^b   Canetta, R ^b   Chylak, V ^b   Cohen, C J ^b   Colombo, N ^b   Conte, P F ^b   Crowther, D ^b   Edmonson, J H ^b   Gennatas, C ^b   Gilbey, E ^b   Gore, M ^b   Guthrie, D ^b   Kaye, S B ^b   Laing, A H ^b   Landoni, F ^b   Leonard, R C ^b   Lewis, C ^b   Liu, P Y ^b   Mangioni, C ^b   Marsoni, S ^b   Meerpohl, H ^b   Omura, G A ^b   Parmar, M K B ^b   Pater, J ^b   Pecorelli, S ^b   Presti, M ^b   Sauerbrei, W ^b   Skarlos, D V ^b   Smalley, R V ^b   Solomon, H J ^b   Stewart, L A ^a   Sturgeon, J F G ^b   Tattersall, M H N ^b   Wharton, J T ^b   Ten Bokkel Huinink, W W ^b   Tomirotti, M ^b   Torri, W ^b   Trope, C ^b   Turbow, M M ^b   Vermorken, J B ^b   Webb, M J ^b   Wilbur, D W ^b   Williams, C J ^b   Wiltshaw, E ^b   Yeap, B Y ^b   more..

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b NONE

Author keywords

Advanced ovarian cancer; Chemotherapy; Meta analysis; Randomized controlled trials; Systematic review

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PLATINUM DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; META ANALYSIS; OVARY CANCER; PRIORITY JOURNAL;

EID: 7844240130     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.710     Document Type: Article

References (47)

1. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K and Franks CR (1989) A comparison of toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28: 57-60
2. Advanced Ovarian Cancer Trialists' Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884-893
3. Alberts DS, Green S, Hunnigan EV, O'Toole R, Stock-Novack D, Anderson P, et al (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomised trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706-717
4. Anderson H, Wagstaff J, Crowther D, Evans A, Johansen K and Franks CR (1988) Comparitive toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 24: 1471-1479
5. Athanassiou A, Pectasides D, Varthalitis J, Barbounis V, Dimitriadis M, et al (1990) Carboplatin (C) versus C + ifosfamide (I) + vincristine (V) + bleomycin (B) in epithelial ovarian cancer (OC). Ann Oncol 1(suppl.): 2-25
6. Bajorin D, Sarosdy MF, Poster DG, et al (1993) Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumours. A multi-institutional study. J Clin Oncol 11: 598-606
7. Bell DR, Woods RK, Levi JA, Fox RM and Tattersall MHN (1982) Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cisdiamminedichloroplatimim. Aust NSK Med 12: 245-249
8. Belpomme D, Bugat R, Rives M, Pinon G, Roullet B, Facchini T, et al (1992) Carboplatin versus cisplatin as first line therapy in stage III-IV ovarian carcinoma: results of an ARTAC phase III trial. Proc Am Soc Clin Oncol 11: abstract 722
9. Carmo-Pereira J, Oliveira Costa F and Henriques E (1983). Cisplatinum, adriamycin and hexamethylmelamine vs cyclophosphamide in advanced ovarian carcinoma. Cancer Chemother Pharmacol 10: 100-103
10. Chalmers I and Haynes B (1994) Reporting, updating and correcting systematic reviews of the effects of health care. Br Med J 309: 862-865
11. Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, et al (1983) Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second-look) operation. Am J Obstet Gynecol 145: 955-965
12. Conte PF, Bruzzone M, Carnin F, Chiara S, Donadio M, Facchini V, et al (1991) Carboplatin, doxorubicin and cyclophosphamide versus cisplatin, doxorubicin and cyclophosphamide: a randomised trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 9: 658-663
13. Decker DG, Thomas MD, Fleming R, Malkesian GD, Webb MD, Jefferies JA et al (1982) Cyclophosphamide plus cisplatinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 60: 418-427
14. De Oliveira CF, Lacave AJ, Villani C, Wolff JP, Di Re F, Namer M, et al (1990) Randomised comparison of cyclophosphamide, doxorubicin and cisplatin for the treatment of advanced ovarian cancer. Eur J Gynaecol Oncol 11: 323-330
15. Early Breast Cancer Trialists' Group (1990) Treatment of early breast cancer. Vol 1. In Worldwide Evidence 1985-1990. Oxford University Press: Oxford
16. Edmonson JH, McCormack GM, Wieand HS, Kugler HW, Krook JE, Stanhope CR, et al (1989) Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst 81: 1500-1504
17. Freedman LS (1982) Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1: 121-129
18. Gennatas C, Alamanos J, Dardoufas C, Kovaris J and Androulakis G (1992) Carboplatin, epirubicin and cyclophosphamide versus cisplatin, epirubicin and cyclophosphamide: a phase III randomised trial in stages III and IV epithelial ovarian cancer. Proc Am Soc Clin Oncol 11: (abstract 720)
19. GICOG (1992) Long-term results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide and adriamyein in advanced ovarian cancer. Gynecol Oncol 45: 115-117
20. Gynaecological Group, Clinical Oncological Society of Australia and the Sydney Branch. Ludwig Institute for Cancer Research (1986) Chemotherapy of advanced ovarian adenocarcinoma: a randomised comparison of combination versus sequential therapy using chlorambucil and cisplatin. Gynecol Oncol 23: 1-13
21. Harvey HA, Lipton A, Simmonds M, White D, Gottlieb R, Bernath AM, et al (1982) A randomised trial of Alkeran versus cyclophosphamide, hexamethylmelamine, Adriamycin and cisplatinum combination chemotherapy in advanced ovarian carcinoma. Clin Res 30: 418
22. Horwich A, Sleijfer D, Fossa S, et al (1994) A trial of carboplatin-based chemotherapy in good prognosis metastatic testicular non-seminoma. Proc Am Soc Clin Oncol 13: 231 (abstract 709)
23. Kato T, Nishimura H, Yamabe T, Terashima Y, Kasamatsu T, Hirabayashi K et al (1988) Phase III study of carboplatin for ovarian cancer. Jpn J Cancer Chemother 15: 2297-2304
24. Leonard RC, Smart GE, Livingstone JRB, Cornbleet MA, Kerr GR, Fletcher S, et al (1989) Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. Cancer Chemother Pharmacol 23: 105-110
25. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, et al Randomised trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 81: 1464-1471
26. Masding J, Sarkar T, White JF, Barley VL, Chawla SL, Boesen T, et al (1990) Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol 97: 342-351
27. Meerpohl HG, Kuhnle J, Sauerbrei W, Achterrach W and Pfeiderer A (1990) Cyclophosphamide/cisplatin (CTX/PT) vs CTX/carboplatin (CarboPT) in advanced ovarian carcinoma: a randomised multicentre study. J Cancer Res Clin Oncol 16: 1120
28. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al (1986) A randomised trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 57: 1725-1730
29. Ovarian Cancer Meta-analysis Project (1991) CP versus CAP chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9: 1664-1679
30. Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, et al (1992) A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 65: 275-281
31. Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, et al (1996) Carbo alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Cooperative Oncology Study Group. Eur J Cancer 32: 421-428
32. Sturgeon JFG, Fine S, Gospodarowicz MK, Dembo AJ, Bean HA, Bush RS et al (1982) A randomised trial of melphalan alone vs combination chemotherapy in advanced ovarian cancer. Proc Am Soc Clin Oncol 1: (abstract 108)
33. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carimchael J, et al (1992) Cisplatin cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomised phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 10: 718-726
34. Taylor AE, Wiltshaw E, Gore M, Fryatt I and Fisher C (1994) Long-term follow up of the first randomised study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12: 2066-2070
35. Ten Bokkel Huinik WW, van der Burg ME, van Oosterom AT, Neijt JP, George M, Gustalla JP, et al (1988) Carboplatin in combination chemotherapy for ovarian cancer. Cancer Treat Rev 15:(suppl.) 9-15
36. Tomirotti M, Perrone S, Gie P, Canaletti R, Carpi A, Biasoli R, et al (1988) Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomised trial. Tumori 74: 573-577
37. Torri V on behalf of the International Ovarian Neoplasm Studies (1996) Randomised study of cyclophosphamide, doxorubicin and cisplatin (CAP) vs single-agent carboplatin in ovarian cancer patients requiring chemotherapy: interim results of ICON2, Proc Am Soc Clin Oncol 15: 280 (abstract 752)
38. Trope C, Anderson H, Björkholm E, Frankendal B, Himmelman A, Högberg T, et al (1998) Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer. Ten-year survival results from a prospective randomised study by the Swedish Cooperative Ovarian Cancer Study Group (in press)
39. Wadler S, Yeap B, Vogl S and Carbone P (1996) Randomised trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian cancer: initial and long-term results: Eastern Cooperative Oncology Study Group E2878. Cancer 77: 733-742
40. Wilbur DW, Rentschler RE, Wagner RJ, Keeney ED, King A and Hilliard DA (1987) Randomised trial of the addition of cisplatin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma. J Surg Oncol 34: 165-169
41. Williams CJ, Mead GM, Macbeth FR, Thompson J. Whitehouse JMA, MacDonald H, et al (1985) Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomised trial. J Clin Oncol 3: 1455-1452
42. Wiltshaw E, Evans B, Rustin G, Gilbey H, Baker J and Barker G (1986) A prospective randomised trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4: 722-729
43. Yusuf S, Peto R, Lewis J, Collins R and Sleight T (1985) Beta blockade during and after myocardial infarction: an overview of randomised clinical trials. Prog Cardiov Dis 27: 335-371
44. Crowther D (1996) A randomised trial of chemotherapy in advanced residual (stage lib- IV) ovarian cancer. Manchester Ovarian Cancer Clinical Study Group protocol. (Unpublished)
45. Turbow MM (1980) Chemotherapy of advanced ovarian cancer: Adriamycin-cyclophosphamide versus platinum-Adriamycin-cyclophosphamide. Northern California Oncology Group protocol 5091. (Unpublished)
46. Gilby E, Pollard W, Bamford D, Barley V, Jelen I, Hale BT, et al. Ovarian Cancer Trial, 1986. Southwest Oncology Study. (Unpublished)
47. Medical Research Council Gynaecological Cancer Working Party. Inadequacy of trials of chemotherapy in advanced ovarian carcinoma: a randomised trial of three regimens. (Unpublished)